Condition Lookup

Start typing to search for a specific condition, or select a specialty to see all of its conditions

Sub-Category:

Alport Syndrome

Specialty: Genetics

Category: Genetic Contributions to Common Diseases

Symptoms:
hematuria (blood in urine); proteinuria (protein in urine); progressive kidney failure; hearing loss; ocular abnormalities (e.g., anterior lenticonus, macular thinning)

Root Cause:
Mutations in the COL4A3, COL4A4, or COL4A5 genes disrupt the structure of type IV collagen in the basement membranes of the kidney, ear, and eye, leading to tissue damage.

How it's Diagnosed: videos
Diagnosed through genetic testing, family history, and kidney biopsy.

Treatment:
Treated with ACE inhibitors or ARBs to slow kidney damage, and kidney transplant for end-stage renal disease.

Medications:
ACE inhibitors or ARBs are commonly prescribed to reduce proteinuria and slow kidney disease progression. Other medications include diuretics to manage fluid retention and anemia treatments like erythropoiesis-stimulating agents in advanced kidney disease.

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 50,000 live births; X-linked inheritance accounts for about 85% of cases.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of Alport syndrome, presence of COL4A5 mutations (X-linked), or COL4A3/COL4A4 mutations (autosomal recessive or dominant).

Prognosis: The expected outcome or course of the condition over time.
Variable depending on the mutation and inheritance pattern. Progression to ESRD occurs by age 30 in most males with X-linked Alport syndrome. Early management improves outcomes.

Complications: Additional problems or conditions that may arise as a result of the original condition.
End-stage renal disease, hearing impairment, visual disturbances, cardiovascular complications, and psychological impact from chronic illness.

Polycystic Kidney Disease (PKD1, PKD2 mutations)

Specialty: Genetics

Category: Genetic Contributions to Common Diseases

Sub-category: Kidney Disorders

Symptoms:
abdominal or flank pain; hematuria (blood in urine); frequent urinary tract infections; high blood pressure; kidney stones; progressive kidney failure; enlarged kidneys

Root Cause:
Genetic mutations in the PKD1 or PKD2 genes cause abnormal development of fluid-filled cysts in the kidneys, leading to progressive kidney damage.

How it's Diagnosed: videos
Diagnosed with imaging (e.g., ultrasound, MRI) and genetic testing.

Treatment:
Treated with tolvaptan to slow cyst growth, blood pressure management with ACE inhibitors/ARBs, and dialysis or kidney transplant for advanced disease.

Medications:
Tolvaptan (a vasopressin receptor antagonist) is often prescribed to slow cyst growth and preserve kidney function. Blood pressure medications such as ACE inhibitors or ARBs are used to control hypertension. Pain management may include acetaminophen or nonsteroidal anti-inflammatory drugs (with caution).

Prevalence: How common the health condition is within a specific population.
Affects approximately 1 in 400 to 1,000 individuals worldwide, making it one of the most common genetic kidney disorders.

Risk Factors: Factors or behaviors that increase the likelihood of developing the condition.
Family history of PKD, presence of PKD1 mutations (associated with more severe disease compared to PKD2 mutations), and advanced age.

Prognosis: The expected outcome or course of the condition over time.
Progression to end-stage renal disease (ESRD) occurs in about 50% of patients by age 60. Lifelong management can improve quality of life and delay complications.

Complications: Additional problems or conditions that may arise as a result of the original condition.
Kidney failure requiring dialysis or transplant, chronic pain, hypertension, liver cysts, cardiovascular disease, and increased risk of aneurysms.